

Regional Community Coalition

All Member Call

April 26, 2022



Housekeeping



Please mute your microphones during the presentation.



Enter your questions in the chat box.



Share your experience with the group.

Roll Call



Please enter the following information in the chat:

- A. Name
- B. Organization
- C. Coalition name and location
- D. Activities and/or updates

Community Coalition PULSE Check

Regular Meetings

How can Mountain-Pacific Quality Health support you?

Coalition Members

Update member names and contact information.
Are there additional or potential partners for recruitment to report?

Metrics and Data

Please identify the three most important areas of focus in your community?

Next Steps for Coalitions

- Coalition participation agreements
- Community charter, 2022
- All Member meeting
July 26, 2022

Five Goals for Community Coalitions

1 Opioid ADEs and reducing deaths

2 Chronic disease management

3 Care coordination

4 Emergency preparedness plans

5 Immunizations

What is new with Mountain-Pacific?

Coalition Updates

Mountain-Pacific Quality Health staff

General Updates

- Vaccinations
- Data
- Nursing homes

CDC recommends pneumococcal vaccination for

- Adults 65 years old and older
- Adults 19 through 64 years old with certain underlying medical conditions or other risk factors:
 - Alcoholism
 - Cerebrospinal fluid leak
 - Chronic heart/liver/lung disease
 - Chronic renal failure*
 - Cigarette smoking
 - Cochlear implant
 - Congenital or acquired asplenia*
 - Congenital or acquired immunodeficiencies*
 - Diabetes
 - Generalized malignancy*
 - HIV infection*
 - Hodgkin disease*
 - Iatrogenic immunosuppression*
 - Leukemia*
 - Lymphoma*
 - Multiple myeloma*
 - Nephrotic syndrome*
 - Sickle cell disease or other hemoglobinopathies*
 - Solid organ transplants*

* Considered an immunocompromising condition

Adult Pneumonia Recommendations

Vaccine	<i>Pneumovax 23</i> (PPSV23)	<i>Prevnar 13</i> (PCV13)	<i>Vaxneuvance</i> (PCV15)	<i>Prevnar 20</i> (PCV20)
Type of vaccine ^a	polysaccharide	conjugate ^b	conjugate ^b	conjugate ^b
Additional serotypes covered ^c	2, 8, 9N, 10A, 11A, 12F, 15B,17F, 20, 22F, 33F	6A	6A, 22F, 33F	6A, 8, 10A, 11A, 12F, 15B, 22F, 33F
Approved age and dose	<p>≥50 years old</p> <p>≥2 years old at increased risk for pneumococcal disease^d</p> <ul style="list-style-type: none"> single 0.5 mL dose (IM or subcutaneous) 	<p>6 weeks to 5 years old:</p> <ul style="list-style-type: none"> 4-dose series (each dose 0.5 mL IM) <p>≥6 years old</p> <ul style="list-style-type: none"> single 0.5 mL IM dose 	<p>≥18 years old^f</p> <ul style="list-style-type: none"> single 0.5 mL IM dose 	<p>≥18 years old^f</p> <ul style="list-style-type: none"> single 0.5 mL IM dose
Comments	~8% to 15% of invasive disease (depending on age) is caused by serotypes only covered by this vaccine. ³	<p>Routine vaccination workhorse for kids.</p> <p>Recommended in adults with certain conditions.</p> <p>Only covers ~30% of serotypes causing invasive disease.³</p>	<p>Covers additional serotypes causing ~15% of invasive disease NOT covered by PCV13 in patients ≥19 years old.³</p> <p>Does NOT provide additional coverage compared to PCV20.</p>	<p>Covers additional serotypes causing ~30% of invasive disease NOT covered by PCV13 in patients ≥19 years old.³</p>
Immunity	Models project linear decline over 15 years. ³	<p>Models project no decline for 5 years, followed by linear decline over 10 years.³</p> <p>Evidence suggests these may have a greater immune response than PPSV23 against most serotypes they have in common.³⁻⁵</p>		
Cost per dose ^e	~\$120	~\$215	~\$220	~\$240

Pneumonia Vaccines

Recombinant Zoster Vaccine

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged \geq 19 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, 2022

Weekly / January 21, 2022 / 71(3); 80-84

Summary

What is already known about this topic?

Immunocompromised persons experience a higher incidence of herpes zoster and related complications. On July 23, 2021, the Food and Drug Administration expanded the indication for use of recombinant zoster vaccine (RZV) to include immunodeficient or immunosuppressed adults.

What is added by this report?

On October 20, 2021, the Advisory Committee on Immunization Practices recommended 2 RZV doses for prevention of herpes zoster and related complications in immunodeficient or immunosuppressed adults aged \geq 19 years.

What are the implications for public health practice?

RZV is the first herpes zoster vaccine approved for use in immunocompromised persons. With moderate to high vaccine efficacy and an acceptable safety profile, RZV has the potential to prevent considerable herpes zoster incidence and related complications.

Resources

Pneumococcal Vaccination: Information for Health Care Professionals

<https://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html>

PneumoRecs VaxAdvisor Mobile App for Vaccine Providers

<https://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html>

Pneumococcal Advisory Committee on Immunization Practices (ACIP) Vaccine Recommendations

<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html>

Pneumococcal Vaccine Timing for Adults

<https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf>

You Call the Shots Web-based Training

<https://www.cdc.gov/vaccines/ed/youcalltheshots.html>

Adult Immunization Schedule

<https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>

Vaccine Information Sheets (VIS)

- Pneumococcal Conjugate Vaccine <https://www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv.pdf>
- Pneumococcal Polysaccharide Vaccine <https://www.cdc.gov/vaccines/hcp/vis/vis-statements/ppv.pdf>

Polling Question One



- 1. What areas of quality improvement are you currently working on in your coalitions?**
 - a) Opioid best practices
 - b) Medication safety/adverse drug events
 - c) Admissions/readmissions
 - d) Nursing home quality
 - e) Emergency management
 - f) Immunizations
 - g) Chronic care management

Polling Question Two



- 2. In what areas of quality improvement do you need additional support?**
- a) Opioid best practices
 - b) Medication safety/adverse drug events
 - c) Admissions/readmissions
 - d) Nursing home quality
 - e) Emergency management
 - f) Immunizations
 - g) Chronic care management

Coalition Highlights



Guam Diabetes
Alert Day Drive-
Thru Mini
Health Fair

March 26, 2022

Hagatna, Guam

Summary

100 Risk Assessments
58 Total screened
33 Health Professional Consults


Highest BG/BP:
424 mg/dL 166/84

Screening Questions

- ◇ How old are you?
- ◇ What is your gender?
- ◇ (If woman) Have you ever been diagnosed with gestational diabetes?
- ◇ Do you have a mother, father, sister, or brother with diabetes?
- ◇ Have you ever been diagnosed with high blood pressure?
- ◇ Are you physically active?
- ◇ What race or ethnicity best describes you?
- ◇ What is your height? What is your weight? (BMI question)


ADA Diabetes Risk Assessment

Low Risk < 5
33%




High Risk > 5
67%

Blood Pressure



Random Blood Glucose



What are you doing in your coalition?

Challenges

Interventions

Outcomes

Bright Spots

Upcoming Events

July 26, 2022: Regional coalition all member quarterly call

https://mpqhf.zoom.us/meeting/register/tJARfu2rrDMpGN1hF-v48NCvaZNnD_ng6JBK

April 30, 2022: National prescription drug take back

<https://www.dea.gov/takebackday>

May 6 and May 20, 2022: Opioid risk assessments, “Eating the Elephant One Bite at a Time”

https://mpqhf.zoom.us/webinar/register/WN_XOoL2wjDRs6S_wzF3EV0gw

Second Tuesday of each month: Nursing Home ECHO: Geriatrics workforce enhancement program (GWEP) team meeting - five-part series

https://echo.zoom.us/meeting/register/tJYodu6hqDwuGtFajh5DVU_xnsHk4cZZLj8W

Every Wednesday: Mountain-Pacific Quality Health “It’s Worth a Shot” series

[Webinar Registration – Zoom](#)

Thank you!

Next regional coalition all member call:

July 26, 2022

11:00 AM HST | 1:00 PM AKST | 3:00 PM MST

Guam/Saipan – July 27, 2022 | 8:00 AM